Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Susan D Croll

Lynn Macdonald

Andrew J Murphy

Ying Hu

Min Gao

Alexander O Mujica

Carmelo Romano

Ka-Man Venus Lai

Stanley J Wiegand

Yajun Tang

Jeffrey D Lee

Brian Zambrowicz

Jose F Rojas

Michael L LaCroix-Fralish

Nicole M Alessandri-Haber

Meghan Drummond Samuelson

Claudia Gonzaga-Jauregui

Charleen Hunt

Susannah Brydges

Burcin Ikiz

Robert Breese

Michael Lacroix-Fralish

The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human artemin. Methods for using anti-artemin antibodies and antigen-binding fragments are also provided.

Human antibodies to artemin and methods of use thereof

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.

Mouse comprising a humanized TRKB locus

The present invention provides antibodies that bind specifically to TrkB and methods of using the same. According to certain embodiments, the antibodies of the invention are agonist antibodies that are neuroprotective, as shown by their effect on enhancing the survival of retinal ganglion cells in vitro. As such, these agonist antibodies may be used to treat diseases or disorders of the eye, such as, but not limited to glaucoma. In addition, other neuronal diseases or disorders may benefit from treatment with these agonist antibodies, including any disease or disorder characterized in part by neuronal damage. In certain embodiments, the invention includes antibodies that bind TrkB and mediate cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies.

Anti-TrkB monoclonal antibodies and methods of use

This disclosure relates to an animal model of human disease. More specifically, this disclosure relates to a rodent model of mood disorders such as unipolar depression and an anxiety disorder. Disclosed herein are genetically modified rodent animals that carry a humanized G protein-coupled receptor 156 (GPR156) gene that encodes a mutant human GPR156 protein comprising Asp at an amino acid position corresponding to position 533 in a full length wild type human GPR156 protein.

Rodent model of mood disorders

[object Object]

The present invention provides antibodies that bind to human GFR&#x3b1;3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR&#x3b1;3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR&#x3b1;3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.

Human antibodies to GFR&#x3b1;3 and methods of making thereof

An animal model for motor neuron dysfunction in disease, e.g., amyotrophic lateral sclerosis (ALS), comprising a genetically modified non-human animal that comprises a genetically modified DR6 allele and exhibits normal phenotypes at birth and for a few weeks or months after birth. However, as the non-human animal ages, it develops motor neuron dysfunction that presents as one or more ALS-like symptoms, which may progress rapidly after onset. Methods of identifying candidate agents that may be used to prevent, delay or treat ALS are also provided.

Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception

Human antibodies to GFR alpha3 and methods of reducing pain associated with GFR alpha3-related diseases

Human antibodies to GFR &#x3b1;3 and methods of treating pain associated with osteoarthritis or bone cancer

Human antibodies to GFR&#x3b1;3 and methods of use thereof

Growing community of inventors

Putnam Valley, NY, United States of America

Susan D Croll